Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3293767 | 0.79 | CYP19A1 (0.37) | ALDH1A1TDP1MAPTHPGDL3MBTL1 | |
| SCHEMBL3292618 | 0.78 | CTSB (0.54) | ALDH1A1TDP1MAPTHPGDNPC1 | |
| SCHEMBL3638298 | 0.75 | MAPT (0.46) | ALDH1A1MAPTHPGDCYP1A2NPC1 | |
| SCHEMBL1614175 | 0.75 | MAPT (0.64) | ALDH1A1TDP1MAPTHPGDCYP1A2 | |
| SCHEMBL589908 | 0.74 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPTCYP3A4L3MBTL1 | |
| SCHEMBL10810296 | 0.74 | MAPT (0.46) | ALDH1A1TDP1MAPTHPGDCYP1A2 | |
| SCHEMBL9507659 | 0.73 | ALDH1A1 (0.49) | ALDH1A1TDP1MAPTHPGDCYP1A2 | |
| SCHEMBL5017959 | 0.73 | CDC25B (0.50) | ALDH1A1TDP1MAPTHPGDCYP1A2 | |
| SCHEMBL21206935 | 0.72 | MAPT (0.61) | ALDH1A1TDP1MAPTHPGDCYP1A2 | |
| SCHEMBL31478092 | 0.72 | TDP1 (0.53) | ALDH1A1TDP1MAPTCYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016116900-A1 | INHIBITORS OF TRKA KINASE | GVK BIOSCIENCES PRIVATE LIMITED (IN) | 2016-07-28 | — | — | WO | disclosed |
| US-7732483-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-7732483-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-7696203-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-13 | — | — | US | disclosed |
| US-7696203-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-13 | — | — | US | disclosed |
| US-7696203-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-13 | — | — | US | disclosed |
| US-20080242664-A1 | DNA-PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20080242664-A1 | DNA-PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-7402607-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-07-22 | — | — | US | disclosed |
| US-7402607-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-07-22 | — | — | US | disclosed |
| US-7402607-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-07-22 | — | — | US | disclosed |
| EP-1869021-A1 | DNA-PK INHIBITORS | Kudos Pharmaceuticals Ltd (GB) | 2007-12-26 | — | — | EP | disclosed |
| US-20070238731-A1 | Dna-Pk Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-20070238731-A1 | Dna-Pk Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-20070238731-A1 | Dna-Pk Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| EP-1794151-A1 | DNA-PK INHIBITORS | Kudos Pharmaceuticals Limited (GB) | 2007-06-13 | — | — | EP | disclosed |
| US-20060264427-A1 | 3-amino-N-[4-(2-morpholin-4-yl-1-benzopyran-4-one)-dibenzofuran-1-yl]-propionamides ; anticancer, antitumor agents | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| WO-2006109081-A1 | DNA-PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| US-20060106025-A1 | e.g. 2-Chloro-N-[4-(2-morpholin-4-yl-4-oxo-4H-chromen-8-yl)-dibenzothiophen-1-yl]-acetamide; anticancer, antitumor agents | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-05-18 | — | — | US | disclosed |
| WO-2006032869-A1 | DNA-PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242664-A1 | DNA-PK INHIBITORS | XRCC6, XRCC5, POLK | ALDH1A1 4383/4885TDP1 259/4885MAPT 4209/4885 |
| US-20070238731-A1 | Dna-Pk Inhibitors | XRCC6, XRCC5, POLK | ALDH1A1 4317/4885TDP1 296/4885MAPT 4277/4885 |
| US-20060106025-A1 | e.g. 2-Chloro-N-[4-(2-morpholin-4-yl-4-oxo-4H-chromen-8-yl)-dibenzothiophen-1-yl]-acetamide; anticancer, antitumor agents | NR4A1, NR5A2, NR2E1 | ALDH1A1 2325/4885TDP1 4236/4885MAPT 4590/4885 |
| US-20060264427-A1 | 3-amino-N-[4-(2-morpholin-4-yl-1-benzopyran-4-one)-dibenzofuran-1-yl]-propionamides ; anticancer, antitumor agents | POLK, DCK, POLN | ALDH1A1 1666/4885TDP1 157/4885MAPT 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.